Stephane Laporte
Dr. St茅phane Laporte earned his undergraduate degree in biology and biotechnology at Universit茅 de Sherbrooke before completing his M.Sc. and Ph.D. in pharmacology, where he developed expertise in G protein鈥揷oupled receptor (GPCR) signaling and molecular pharmacology. He subsequently pursued postdoctoral training at Duke University, focusing on receptor trafficking and translational GPCR biology, and established a research program dedicated to the mechanistic dissection of GPCR function in cardiovascular and endocrine systems.
Dr. Laporte is now Professor of Medicine since 2014 and a senior investigator at the Research Institute of the 海角社区 Health Centre (RI-MUHC). His research centers on ligand-directed signaling, allosteric modulation, and structure-based drug discovery targeting class A GPCRs, particularly the angiotensin II type 1 receptor (AT1R). By integrating structural modeling with quantitative functional pharmacology, his work defines mechanistic principles of GPCR signaling bias and translates them into next-generation therapeutics.
He has published over 100 peer-reviewed articles (>14,000 citations; h-index 53), delivered more than 60 invited lectures internationally, and generated multiple patents and licensed technologies. Dr. Laporte has held several leadership roles, including Director of the Imaging Core Facility at RI-MUHC and Director of Research for the Division of Endocrinology at 海角社区. He previously served as Co-Director and Director of the Quebec Drug Research Network and as Scientific Advisor to FRQS.
His current initiatives focus on advancing GPCR-targeted therapies through multi-institutional collaborations, with applications in cardiovascular disease, cancer, reproductive biology, and orphan GPCR research.